Source: Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management October 2019
Whilst Ibrutinib has been a life saver for patients a very significant number have to suspend or stop treatment because of side effects (AEs) .
Specific adverse events (AEs), include myalgias, arthralgias, rash, bruising and, less commonly, serious bleeding, hypertension, or atrial fibrillation. Dose adjustments of ibrutinib can often help alleviate many of these AEs, but some can be dose limiting for individual patients.
This article looks at what we need from the next generation of BTK inhibitors and goes into some detail about what is on the horizon. They include the following: Improving Tolerability With More Selective BTK Inhibitors, Overcoming Acquired BTK inhibitor Resistance and the Potential for Fixed-Duration BTK Inhibitor Therapy.
More detail here: clinicaloptions.com/oncolog...
Jackie
CAR-T for CLL Hits Goal of Mid-Stage Trial - All patients had progressed on BTK inhibitors & most had failed venetoclax - MedPageToday, 6/12
BTK inhibitor challenges by Dr. Nicole Lamanna 
